Edna Chow Maneval

2.6k total citations · 1 hit paper
41 papers, 1.4k citations indexed

About

Edna Chow Maneval is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Edna Chow Maneval has authored 41 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 16 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Edna Chow Maneval's work include Prostate Cancer Treatment and Research (20 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Lung Cancer Treatments and Mutations (12 papers). Edna Chow Maneval is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Lung Cancer Treatments and Mutations (12 papers). Edna Chow Maneval collaborates with scholars based in United States, Netherlands and Switzerland. Edna Chow Maneval's co-authors include Isan Chen, Jeffrey H. Hager, Nhin Lu, Jing Qian, Dan Brigham, John Sensintaffar, Gang Shao, James D. Joseph, Beatrice Darimont and Dana E. Rathkopf and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Edna Chow Maneval

39 papers receiving 1.4k citations

Hit Papers

A Clinically Relevant Androgen Receptor Mutation Confers ... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
    2013 455 citations James D. Joseph, Nhin Lu et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edna Chow Maneval United States 15 1.1k 490 479 387 267 41 1.4k
J. W. Clark United States 15 937 0.8× 331 0.7× 443 0.9× 490 1.3× 159 0.6× 26 1.5k
Géralyn C. Trudel United States 11 1.1k 1.0× 417 0.9× 365 0.8× 434 1.1× 400 1.5× 24 1.5k
Consuelo Buttigliero Italy 23 1.0k 0.9× 397 0.8× 411 0.9× 692 1.8× 247 0.9× 91 1.7k
Jean‐Christophe Eymard France 15 987 0.9× 379 0.8× 512 1.1× 645 1.7× 213 0.8× 47 1.5k
Vanessa Martins United Kingdom 10 929 0.8× 331 0.7× 416 0.9× 201 0.5× 236 0.9× 14 1.3k
De Phung United States 19 1.7k 1.5× 612 1.2× 289 0.6× 495 1.3× 618 2.3× 46 2.0k
Kim Chi Canada 20 799 0.7× 520 1.1× 872 1.8× 636 1.6× 229 0.9× 49 1.9k
Toshinari Yamasaki Japan 23 684 0.6× 361 0.7× 581 1.2× 391 1.0× 88 0.3× 117 1.4k
Mary Barrett United Kingdom 4 589 0.5× 226 0.5× 327 0.7× 181 0.5× 160 0.6× 7 923
Magdolna Dank Hungary 19 499 0.4× 394 0.8× 419 0.9× 730 1.9× 166 0.6× 120 1.5k

Countries citing papers authored by Edna Chow Maneval

Since Specialization
Citations

This map shows the geographic impact of Edna Chow Maneval's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edna Chow Maneval with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edna Chow Maneval more than expected).

Fields of papers citing papers by Edna Chow Maneval

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edna Chow Maneval. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edna Chow Maneval. The network helps show where Edna Chow Maneval may publish in the future.

Co-authorship network of co-authors of Edna Chow Maneval

This figure shows the co-authorship network connecting the top 25 collaborators of Edna Chow Maneval. A scholar is included among the top collaborators of Edna Chow Maneval based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edna Chow Maneval. Edna Chow Maneval is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Junttila, Melissa R., Claire E. Repellin, Jason E. Long, et al.. (2024). 62 (PB050): ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations. European Journal of Cancer. 211. 114589–114589. 2 indexed citations
2.
Hong, Min Hee, Alexander I. Spira, Ki Hyeong Lee, et al.. (2023). 1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations. Annals of Oncology. 34. S769–S769. 5 indexed citations
3.
Bardia, Aditya, Ingrid A. Mayer, Eric P. Winer, et al.. (2022). The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer. Breast Cancer Research and Treatment. 197(2). 319–331. 14 indexed citations
4.
Tolcher, Anthony W., Shivaani Kummar, Manish R. Patel, et al.. (2021). Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 2553–2553. 1 indexed citations
5.
Robinson, Giles, Ami V. Desai, Karen Gauvain, et al.. (2019). PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. Neuro-Oncology. 21(Supplement_6). vi186–vi186. 1 indexed citations
6.
Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2017). Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clinical Cancer Research. 23(14). 3544–3551. 64 indexed citations
7.
Sigal, Darren, Marie Tartar, Patrick J. Foley, et al.. (2017). Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. Journal of the National Comprehensive Cancer Network. 15(11). 1317–1322. 32 indexed citations
8.
Rangaraju, Sunitha, Gang Li, Jason Christiansen, et al.. (2017). TRTH-10. PEDIATRIC PHASE 1/1B STUDY OF ENTRECTINIB IN PATIENTS WITH PRIMARY BRAIN TUMORS, NEUROBLASTOMA, AND NTRK, ROS1, OR ALK FUSIONS. Neuro-Oncology. 19(suppl_4). iv53–iv53. 7 indexed citations
9.
Drilon, Alexander, Kamalesh K. Sankhala, Stephen V. Liu, et al.. (2017). Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions. Cancer Research. 77(13_Supplement). CT060–CT060. 13 indexed citations
10.
Smith, Matthew R., Emmanuel S. Antonarakis, Charles J. Ryan, et al.. (2016). Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. European Urology. 70(6). 963–970. 100 indexed citations
11.
Hecht, J. Randolph, Edith Mitchell, Takayuki Yoshino, et al.. (2015). 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Management and Research. 7. 165–165. 9 indexed citations
12.
Wang, Yingbing, Gary A. Ulaner, H. Charles Manning, et al.. (2015). Validation of target engagement using 18F-fluoroestradiol PET in patients undergoing therapy with selective estrogen receptor degrader, ARN-810 (GDC-0810). 56. 565–565. 6 indexed citations
13.
Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2014). ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.. Journal of Clinical Oncology. 32(15_suppl). 5026–5026. 5 indexed citations
14.
Joseph, James D., Nhin Lu, Jing Qian, et al.. (2013). A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509. Cancer Discovery. 3(9). 1020–1029. 455 indexed citations breakdown →
15.
Rathkopf, Dana E., Michael J. Morris, Josef J. Fox, et al.. (2013). Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 31(28). 3525–3530. 204 indexed citations
16.
Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2013). ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 31(6_suppl). 48–48. 19 indexed citations
17.
Leong, Stephen, Sabine Eckhardt, Emily Chan, et al.. (2012). A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70(1). 65–74. 7 indexed citations
18.
Zurita, Amado J., Daniel J. George, Neal D. Shore, et al.. (2011). Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Annals of Oncology. 23(3). 688–694. 33 indexed citations
19.
Zurita, Amado J., Thomas E. Hutson, Mark Kozloff, et al.. (2009). Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). Journal of Clinical Oncology. 27(15_suppl). 5166–5166. 14 indexed citations
20.
Zurita, Amado J., Neal D. Shore, Mark Kozloff, et al.. (2007). Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa). Journal of Clinical Oncology. 25(18_suppl). 5134–5134. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. W. Clark Breakdown of academic impact, for papers by Géralyn C. Trudel Breakdown of academic impact, for papers by Consuelo Buttigliero Breakdown of academic impact, for papers by Jean‐Christophe Eymard Breakdown of academic impact, for papers by Vanessa Martins Breakdown of academic impact, for papers by De Phung Breakdown of academic impact, for papers by Kim Chi Breakdown of academic impact, for papers by Toshinari Yamasaki Breakdown of academic impact, for papers by Mary Barrett Breakdown of academic impact, for papers by Magdolna Dank
Rankless by CCL
2026